Prognostic relevance of HPV infection and p16 overexpression in squamous cell anal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 4, 2015, Pages 819-827

  Mai, Sabine ^a   Welzel, Grit ^a   Ottstadt, Martine ^a   Lohr, Frank ^a   Severa, Sebastin ^a   Prigge, Elena Sophie ^b   Wentzensen, Nicolas ^c   Trunk, Marcus J ^a   Wenz, Frederik ^a   Von Knebel Doeberitz, Magnus ^b   Reuschenbach, Miriam ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DNA; MULTIVARIANT ANALYSIS; PATIENT MONITORING; PATIENT TREATMENT; TUMORS;

COMBINED DETECTIONS; CONFIDENCE INTERVAL; HUMAN PAPILLOMAVIRUS; MULTI VARIATE ANALYSIS; PROGNOSTIC FACTORS; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNIVARIATE ANALYSIS;

DIAGNOSIS;

FLUOROURACIL; MITOMYCIN; PROTEIN P16; VIRUS DNA; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGE; ANUS CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMORADIOTHERAPY; COLOSTOMY; DISTANT METASTASIS; FEMALE; GENDER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; LEUKOPENIA; LEUKOPENIC SEPSIS; LOCAL CONTROL; LOCAL EXCISION; LUNG EMBOLISM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PATIENT HISTORY OF SURGERY; PELVIS LYMPH NODE; PNEUMONIA; PRIORITY JOURNAL; RECTUM ABDOMINOPERINEAL RESECTION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPSIS; SQUAMOUS CELL ANAL CANCER; TREATMENT RESPONSE; AGED; ANALYSIS OF VARIANCE; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; PROGNOSIS; SEX DIFFERENCE; SURVIVAL; TIME; VIROLOGY;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84948401354     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.08.004     Document Type: Article

References (41)

1. . Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-280.
2. . Fraunholz I, Rabeneck D, Weiss C, et al. Combined-modality treatment for anal cancer: Current strategies and future directions. Strahlenther Onkol 2010;186:361-366.
3. . Abbas A, Yang G, Fakih M. Management of anal cancer in 2010. Part 2: Current treatment standards and future directions. Oncology (Williston Park) 2010;24:417-424.
4. . Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000;342:792-800.
5. . zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002;2:342-350.
6. . Ouhoummane N, Steben M, Coutlee F, et al. Squamous anal cancer: Patient characteristics and HPV type distribution. Cancer Epidemiol 2013;37:807-812.
7. . Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-1585.
8. . Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: The HIM cohort study. Lancet 2013;382:877-887.
9. . Darwich L, Canadas MP, Videla S, et al. Prevalence, clearance, and incidence of human papillomavirus type-specific infection at the anal and penile site of HIV-infected men. Sex Transm Dis 2013;40:611-618.
10. . Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012;30(Suppl 5):F24-F33.
11. . Doeberitz M, Vinokurova S. Host factors in HPV-related carcinogenesis: Cellular mechanisms controlling HPV infections. Arch Med Res 2009;40:435-442.
12. . Snijders P J, Steenbergen RD, Heideman DA. HPV-mediated cervical carcinogenesis: Concepts and clinical implications. J Pathol 2006;208: 152-164.
13. . McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus -7 oncoprotein induces kdm6a and kdm6b histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A 2011;108:2130-2135.
14. . McLaughlin-Drubin ME, Park D, Munger K. Tumor suppressor p16ink4a is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci U S A 2013;110:16175-16180.
15. . Reuschenbach M, Seiz M, von Knebel D oeberitz C, et al. Evaluation of cervical cone biopsies for coexpression of p16ink4a and ki-67 in epithelial cells. Int J Cancer 2012;130:388-394.
16. . Allen CT, Lewis JS Jr., El-Mofty SK, et al. Human papillomavirus and oropharynx cancer: Biology, detection and clinical implications. Laryngoscope 2010;120:1756-1772.
17. . Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of H PVassociated p16ink4a expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-1998.
18. . Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomaviruseassociated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24: 736-747.
19. . Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-4301.
20. . Stein AP, Saha S, Yu M, et al. Prevalence of human papill omavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol 2014;27:462-469.
21. . Petrick JL, Wyss AB, Butler AM, et al. Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: Systematic review and meta-Analysis. Br J Cancer 2014;110:2369-2377.
22. . Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363: 24-35.
23. . Gilbert DC, Williams A, Allan K, et al. P16ink4a, p53, EGFR expression and KRAS mutation status in squamous cell cancer s of the anus: Correlation with outcomes following chemo-radiotherapy. Radiother Oncol 2013;109:146-151.
24. . Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping a nd p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol 2014;32:1812-1817.
25. . Yhim HY, Lee NR, Song EK, et al. The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer 2011;129:1752-1760.
26. . Mai SK, Grieger J, Lachmann R, et al. Radiochemotherapy for anal carcinoma: Effectivity and late toxicity. Onkologie 2002;25:55-59.
27. . Mai SK, Welzel G, Hermann B, et al. Long-term outcome after combined radiochemotherapy for anal cancer: Retrospective analysis of efficacy, prognostic factors, and toxicity. Onkologie 2008;31:251-25 7.
28. . Reuschenbach M, Kansy K, Garbe K, et al. Lack of evidence of human papillomavirus-induced squamous cell carcinomas of the oral cavity in southern Germany. Oral Oncol 2013;49:937-942.
29. . Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in notch1. Science 2011;333:1154-1157.
30. . Gaykalova DA, Mambo E, Choudhary A, et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One 2014;9:-93102.
31. . Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-1160.
32. . Ajani JA, Wang X, Izzo JG, et al. Molecular biomarkers correl ate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010;55:1098-1105.
33. Bruland O,Fluge O,Immervoll H,et al. Gene expression reveals two distinct groups of anal carcinomas with clinical implications Br J Cancer 2008 98 1264-1273.
34. . Perrone F, Gloghini A, Cortelazzi B, et al. Isolating p16-positive/HPVnegative oropharyngea l cancer: An effort worth making. Am J Surg Pathol 2011;35:774-777. author reply 777-778.
35. . Koerber SA, Slynko A, Haefner MF, et al. Efficacy and toxicity of chemoradiation in patients with anal cancer: A retrospective analysis. Radiat Oncol 2014;9:113.
36. . Olivatto LO, Vieira FM, Pereira BV, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiother apy in patients with locally advanced anal canal carcinoma. Cancer 2013;119: 2973-2980.
37. . Casadei Gardini A, Capelli L, Ulivi P, et al. KRAS, BRAF and pik3ca status in squamous cell anal carcinoma (SCAC). PLoS One 2014;9: -92071.
38. . Thomas LK, Bermejo JL, Vinokurova S, et al. Chromosomal gains and losses in human papillomavirus-Associated neoplasia of the lower genital tract: A system atic review and meta-Analysis. Eur J Cancer 2014;50:85-98.
39. . Prigge ES, Urban K, Stiegler S, et al. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract a nd head and neck region independent of human papillomavirus and p16(ink4a) status. Hum Pathol 2014;45:2347-2354.
40. . Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 2007; 14:2780-2789.
41. . Mirghani H, Amen F, Blanchard P, et al. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. Int J Cancer 2015;136:1494-1503.